Skip to main content

Table 1 Characteristics of studies included in meta-analysis

From: Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis

Reference numbers

First author

Type of study

Location

Sample size

Morbidities (HAS/DM/DCV/ACE OU BRA)

Outcome (severity and/or mortality)

[14]

Li et al.

Case Series

CHINA

362

HAS/DM/DCV/ACEI/ARB uses

Severity and Mortality

[15]

Giamarellos-Bourboulis et al.

Case Series

GREECE

54

DM/DCV

Severity

[16]

Zhang et al.

Retrospective Cohort

CHINA

19

HAS/DM/DCV

Mortality

[17]

Zhou et al.

Retrospective Cohort

CHINA

191

HAS/DM/DCV

Mortality

[18]

Colombi et al.

Retrospective Cohort

ITALY

236

DM/DCV

Severity

[19]

Li et al.

Cross Sectional

CHINA

548

HAS/DM/DCV/ACEI/ARB use

Severity

[20]

Lei et al.

Retrospective Cohort

CHINA

34

DM/DCV

Severity

[21]

Deng et al.

Retrospective Cohort

CHINA

112

HAS/DM/DCV

Severity

[22]

Guo et al.

Case Series

CHINA

187

HAS/DM/DCV/ACEI/ARB use

Severity

[23]

Huang et al.

Retrospective Cohort

CHINA

41

HAS/DM/DCV

Severity

[24]

Zhang et al.

Case Series

CHINA

140

HAS/DM/DCV

Severity

[25]

Liu et al.

Retrospective Cohort

CHINA

78

HAS/DM/DCV

Severity

[26]

Wang et al.

Retrospective Cohort

CHINA

138

HAS/DM/DCV

Severity

[27]

Guan et al.

Retrospective Cohort

CHINA

1099

HAS/DM/DCV

Severity and Mortality

[28]

Wu et al.

Retrospective Cohort

CHINA

84

HAS/DM/DCV

Mortality

[29]

Zhang et al.

Retrospective Cohort

CHINA

221

HAS/DM/DCV

Severity

[30]

Chen et al.

Retrospective Cohort

CHINA

274

HAS/DM/DCV

Mortality

[31]

Deng et al.

Retrospective Cohort

CHINA

225

HAS/DM/DCV

Mortality

[32]

Wang et al.

Case Series

CHINA

69

HAS/DM/DCV

Severity

[33]

Yang et al.

Retrospective Cohort

CHINA

52

DM/DCV

Mortality

[34]

Guan et al.

Case Series

CHINA

1590

DM/DCV

Mortality

[35]

Zheng et al.

Retrospective Cohort

CHINA

161

HAS/DM/DCV

Severity

[36]

Fan et al.

Retrospective Cohort

CHINA

21

HAS/DM/DCV

Mortality

[37]

Yuan et al.

Case Series

CHINA

27

HAS/DM/DCV

Severity

[38]

Feng et al.

Retrospective Cohort

CHINA

476

HAS/DM/DCV

Severity

[39]

Mao et al.

Case Series

CHINA

214

HAS/DM/DCV

Severity

[40]

Wang et al.

Retrospective Cohort

CHINA

339

HAS/DM/DCV

Mortality

[41]

Simonet et al.

Retrospective Cohort

FRANCE

124

HAS/DM/DCV

Severity

[42]

Chen et al.

Cross Sectional

CHINA

150

HAS

Severity

[43]

Wu et al.

Retrospective Cohort

CHINA

201

HAS

Severity

[44]

Xiang et al.

Cross Sectional

CHINA

49

HAS

Severity

[45]

Wan et al.

Cross Sectional

CHINA

135

HAS/DM/DCV

Severity

[46]

Qin et al.

Retrospective Cohort

CHINA

452

HAS

Severity

[47]

Ruan et al.

Retrospective Cohort

CHINA

150

HAS

Mortality

[48]

Zhang et al.

Retrospective Cohort

CHINA

1128

ACEI/ARB use

Mortality

[49]

Xu et al.

Retrospective Cohort

CHINA

187

HAS

Mortality

[50]

Meng et al.

Case series

CHINA

42

ACEI/ARB use

Severity

[51]

Yang et al.

Retrospective Cohort

CHINA

125

ACEI/ARB use

Severity

[52]

Mancia et al.

Retrospective Cohort

ITALY

6272

ACEI/ARB use

Severity

[53]

Reynolds et al.

Retrospective Cohort

USA

2005

ACEI/ARB use

Severity

  1. DM, diabetes mellitus; HAS, hypertension; DCV, cardiovascular disease; ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers